NC9

NC9 (Cbz-Lys (Acr) -PEG2-dansyl) is an irreversible transglutaminase (TG) inhibitor. NC9 inhibits osteoblast differentiation and mineralization. NC9 destabilizes microtubules. NC9 can be used for the research of osteoblast differentiation[1].

Product Specifications

CAS Number

[1352090-52-8]

Product Name Alternative

Cbz-Lys (Acr) -PEG2-dansyl

UNSPSC

12352005

Target

Glutaminase; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/nc9.html

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(OCC1=CC=CC=C1)N[C@@H](CCCCNC(C=C)=O)C(NCCOCCOCCNS(=O)(C2=C3C=CC=C(N(C)C)C3=CC=C2)=O)=O

Molecular Formula

C35H47N5O8S

Molecular Weight

697.84

References & Citations

[1]Al-Jallad HF, et al. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS One. 2011 Jan 20;6 (1) :e15893.